Eli Lilly, the world's most valuable pharmaceutical company, is heavily investing in technology, building a proprietary on-premise supercomputer with NVIDIA to accelerate AI-driven drug discovery.
The company's growth is overwhelmingly driven by its GLP-1 drugs for diabetes and weight loss, which now constitute the majority of its business and economic value.
Lilly is disrupting the traditional pharmaceutical distribution model with its Lilly Direct platform, selling drugs directly to consumers and creating a multi-billion dollar revenue channel.
The company employs a hybrid R&D strategy, combining the scale of a large pharma company with the agility of smaller, independent research hubs to foster innovation.
12 quotes
Concerns Raised
The current lack of comprehensive biological data limits the predictive power of AI in drug discovery.
The US policy environment, particularly the Inflation Reduction Act, could negatively impact long-term R&D investment incentives.
The high cost and inefficiency of the US clinical trial system remains a major bottleneck to innovation.
The biotech capital markets are in a poor state, with many companies trading below their cash value.
Opportunities Identified
Continued market leadership and expansion in the multi-billion dollar GLP-1 weight loss and diabetes market.
Leveraging proprietary AI and supercomputing capabilities to accelerate drug discovery and create a competitive moat.
Disrupting the pharmaceutical value chain and capturing more margin through the direct-to-consumer Lilly Direct platform.
Developing next-generation therapies, such as one-time gene-editing treatments for high cholesterol.